1. World Health Organization. Global Tuberculosis Report 2017. Geneva (CH): World Health Organization, 2017.
2. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med 2015;372:2127–2135.
3. Trauer JM, Moyo N, Tay EL, et al. Risk of active tuberculosis in the five years following infection . . . 15%? Chest 2016;149:516–525.
4. Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. N Engl J Med 2002;347:1860–1866.
6. Goletti D, Sanduzzi A, Delogu G. Performance of the tuberculin skin test and interferon-γ release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches. J Rheumatol Suppl 2014;91:24–31.
9. Mandalakas AM, Detjen AK, Hesseling AC, Benedetti A, Menzies D. Interferon-gamma release assays and childhood tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 2011;15:1018–1032.
10. Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:45–55.
11. Brighenti S, Andersson J. Induction and regulation of CD8+ cytolytic T cells in human tuberculosis and HIV infection. Biochem Biophys Res Commun 2010;396:50–57.
14. Mazzaccaro RJ, Stenger S, Rock KL, et al. Cytotoxic T lymphocytes in resistance to tuberculosis. Adv Exp Med Biol 1998;452:85–101.
15. Lewinsohn DA, Heinzel AS, Gardner JM, Zhu L, Alderson MR, Lewinsohn DM. Mycobacterium tuberculosis-specific CD8+ T cells preferentially recognize heavily infected cells. Am J Respir Crit Care Med 2003;168:1346–1152.
17. Petruccioli E, Chiacchio T, Pepponi I, et al. First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus. J Infect 2016;73:588–597.
18. QIAGEN. QuantiFERON-TB Gold Plus (QFT-PLUS), ELISA Package Insert [Internet] Venlo (NL): QIAGEN, 2015. [cited 2019 Sep 30]. Available from:
https://www.qiagen.com.
19. Pieterman ED, Liqui Lung FG, Verbon A, et al. A multicentre verification study of the QuantiFERON(
®)-TB Gold Plus assay. Tuberculosis 2018;108:136–142.
20. Petruccioli E, Vanini V, Chiacchio T, et al. Analytical evaluation of QuantiFERON-Plus and QuantiFERON-Gold In-tube assays in subjects with or without tuberculosis. Tuberculosis 2017;106:38–43.
21. Hoffmann H, Avsar K, Gores R, Mavi SC, Hofmann-Thiel S. Equal sensitivity of the new generation QuantiFERON-TB Gold plus in direct comparison with the previous test version QuantiFERON-TB Gold IT. Clin Microbiol Infect 2016;22:701–703.
22. Barcellini L, Borroni E, Brown J, et al. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. Eur Respir J 2016;48:1411–1419.
23. Korea Centers for Disease Control and Prevention. Korean Guidelines for Tuberculosis. 3rd ed. Seoul (KR): Korea Centers for Disease Control and Prevention, 2017.
24. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603–662.
27. Telisinghe L, Amofa-Sekyi M, Maluzi K, et al. The sensitivity of the QuantiFERON(
®)-TB Gold Plus assay in Zambian adults with active tuberculosis. Int J Tuberc Lung Dis 2017;21:690–696.
28. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098–1104.
29. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185–1206.